"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of vorinostat for advanced mesothelioma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a drug called vorinostat (also known as MK0683) for mesothelioma of the lung that continued to grow despite having chemotherapy.
The results of this trial were published in 2015.
More about this trial
- see if vorinostat and best supportive care is better than best supportive care alone for advanced mesothelioma
- learn more about the side effects
Summary of results
The trial team found that giving people with mesothelioma of the lung (pleural mesothelioma) vorinostat after chemotherapy did not improve the length of time they lived for. They do not recommend it as a treatment for people with advanced pleural mesothelioma.
This was an international phase 3 trial. 661 people in 24 countries took part.
The trial was randomised. The people taking part were put into treatment groups by a computer. Neither they nor their doctor could decide which group they were in.
Half the people taking part had vorinostat capsules. The other half had capsules that contain a dummy drug (placebo).
- just under 31 weeks (30.7) for the people taking vorinostat
- just over 27 weeks (27.1) for the people taking the dummy drug
- tiredness and general discomfort (fatigue or malaise)
- difficulty breathing (dyspnoea)
How to join a clinical trial
Dr Paul Robinson
Experimental Cancer Medicine Centre (ECMC)
Sharp & Dohme